STOCKHOLM, Nov. 27, 2019 /PRNewswire/ -- "Something that really differentiates cobitolimod from its competitors is the superior safety profile. Both the approved drugs and those currently being tested in phase III are associated with serious side effects. With an outstanding combination...
from PR Newswire: https://ift.tt/37I1I1d
No comments:
Post a Comment